Myocarditis after COVID‐19 mRNA vaccination in Australia
DescriptionVaccination of 12–16‐year‐old adolescents with Comirnaty (tozinameran, Pfizer–BioNTech) and Spikevax (elasomeran, Moderna) was approved in Australia on 22 July 2021 and 3 September 2021 respectively.
In this report, we describe the initial diagnosis, imaging findings, and short term outcomes for adolescents who presented with COVID‐19 vaccine‐associated myocarditis to the Monash Children’s Hospital, a tertiary centre in Melbourne with a paediatric cardiology service.
The Monash Health human research ethics committee (QA/81618/MonH‐2021‐291293) approved the study.
This MJA research letter shares more.
Learning Outcomes
- Explain key components of the research.
- List main findings.
- Recognise changes in management in response to the research.
Authors: Suraj K Varma, Ari E Horton, Anna L Taylor, Michael R Ditchfield, Sarah A Hope and Srinidhi JV Rao
Article Type: Research letter
N/A
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Infectious Diseases
Medical Practitioner, Doctor-in-Training, Non-Vocationally Registered, Retired, Specialist - Other, Specialist General Practitioner